Intellia Therapeutics, Inc.
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving Intellia Therapeutics, Inc. now
Current reporting with the operating signal separated from the noise.
Is Intellia Therapeutics, Inc. (NTLA) A Good Stock To Buy Now?
Investors are testing whether Intellia Therapeutics, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Intellia Therapeutics, Inc. (NTLA) Discusses Safety Event and Protocol Pause in MAGNITUDE Clinical Trials of Nex-Z Transcript
The story matters when it changes Intellia Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: regulator filings, verified operating scope and liability disclosures.Intellia Therapeutics, Inc. (NTLA) Q2 2025 Earnings Call Transcript
Investors are testing whether Intellia Therapeutics, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Investors are testing whether Intellia Therapeutics, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Latest NTLA filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
Intellia Therapeutics, Inc., quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
No verified period-specific item in the current feed.
SEARCH Q1 COVERAGE →Second quarter
SEARCH Q2 COVERAGE →Third quarter
No verified period-specific item in the current feed.
SEARCH Q3 COVERAGE →Fourth quarter / full year
No verified period-specific item in the current feed.
SEARCH Q4 COVERAGE →